Au, Yan Zi
Gu, Muxin
De Braekeleer, Etienne
Gozdecka, Malgorzata
Aspris, Demetrios
Tarumoto, Yusuke http://orcid.org/0000-0001-6652-9618
Cooper, Jonathan
Yu, Jason http://orcid.org/0000-0001-5203-3603
Ong, Swee Hoe http://orcid.org/0000-0002-3629-5387
Chen, Xi
Tzelepis, Konstantinos http://orcid.org/0000-0002-4865-7648
Huntly, Brian J. P. http://orcid.org/0000-0003-0312-161X
Vassiliou, George http://orcid.org/0000-0003-4337-8022
Yusa, Kosuke http://orcid.org/0000-0002-3442-021X
Funding for this research was provided by:
Kay Kendall Leukaemia Fund (KKL920, KKL920, KKL920)
Takeda Science Foundation
Wellcome Trust (WT206194, WT206194, WT206194, WT206194, WT206194, WT206194, WT206194, RG94424)
Cancer Research UK (C22324/A23015)
Bloodwise (17006)
Article History
Received: 6 August 2019
Revised: 15 July 2020
Accepted: 22 July 2020
First Online: 6 August 2020
Compliance with ethical standards
:
: GSV is a consultant for Kymab and Oxstem. All the remaining authors declare no conflict of interest.